Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT02665416
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇪🇸Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
- Conditions
- Metastatic Cancers
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 264
- Registration Number
- NCT02663232
A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
- Conditions
- HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT02658734
- Locations
- 🇮🇳
Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India
🇮🇳Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India
🇮🇳Artemis Health Institute, Gurgaon, India
Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT02658747
- Locations
- 🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom
🇬🇧Pinderfields General Hospital; Dept of Haematology, Wakefield, United Kingdom
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT02658461
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 578
- Registration Number
- NCT02657434
- Locations
- 🇺🇸
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸Oncology Consultants PA, Houston, Texas, United States
Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe
- Conditions
- Off-Label Use
- Interventions
- Biological: Rituximab
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1408
- Registration Number
- NCT02654379
- Locations
- 🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, LA Coruña, Spain
🇫🇷Hopital Claude Huriez - CHU Lille, Lille, France
🇫🇷Centre Hospitalier Le Mans, Le Mans, France
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT02650713
- Locations
- 🇺🇸
UCLA Cancer Center, Santa Monica, California, United States
🇺🇸Stanford Comprehensive Cancer Center, Stanford, California, United States
🇩🇰Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT02650401
- Locations
- 🇺🇸
Texas Children's Cancer and Hematology Center, Houston, Texas, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT02648048
- Locations
- 🇺🇸
Tulane University Medical School, New Orleans, Louisiana, United States
🇺🇸Suburban Lung Associates, Elk Grove, Illinois, United States
🇺🇸Allied Clinical Research, Reno, Nevada, United States